Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
Moodys
Harvard Business School
McKinsey

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR IXAZOMIB CITRATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ixazomib Citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00963820 ↗ Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma Completed Millennium Pharmaceuticals, Inc. Phase 1 2009-10-01 The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM). Secondary objectives include pharmacokinetics and response rates.
NCT01415882 ↗ Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Recruiting National Cancer Institute (NCI) Phase 2 2012-01-31 This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01415882 ↗ Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Recruiting Mayo Clinic Phase 2 2012-01-31 This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01718743 ↗ Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Active, not recruiting Millennium Pharmaceuticals, Inc. Phase 2 2012-12-03 This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
NCT01718743 ↗ Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Active, not recruiting National Cancer Institute (NCI) Phase 2 2012-12-03 This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
NCT01718743 ↗ Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Active, not recruiting M.D. Anderson Cancer Center Phase 2 2012-12-03 This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ixazomib Citrate

Condition Name

Condition Name for Ixazomib Citrate
Intervention Trials
Recurrent Plasma Cell Myeloma 11
Plasma Cell Myeloma 7
Refractory Plasma Cell Myeloma 7
Multiple Myeloma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ixazomib Citrate
Intervention Trials
Neoplasms, Plasma Cell 24
Multiple Myeloma 24
Lymphoma 4
Lymphoma, Mantle-Cell 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ixazomib Citrate

Trials by Country

Trials by Country for Ixazomib Citrate
Location Trials
United States 141
Brazil 19
United Kingdom 18
Italy 17
Germany 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ixazomib Citrate
Location Trials
Minnesota 15
California 9
Texas 8
Georgia 7
Washington 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ixazomib Citrate

Clinical Trial Phase

Clinical Trial Phase for Ixazomib Citrate
Clinical Trial Phase Trials
Phase 3 4
Phase 2 19
Phase 1/Phase 2 9
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ixazomib Citrate
Clinical Trial Phase Trials
Active, not recruiting 18
Recruiting 10
Completed 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ixazomib Citrate

Sponsor Name

Sponsor Name for Ixazomib Citrate
Sponsor Trials
National Cancer Institute (NCI) 28
Millennium Pharmaceuticals, Inc. 10
Mayo Clinic 10
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ixazomib Citrate
Sponsor Trials
Other 34
NIH 28
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Medtronic
AstraZeneca
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.